Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

• DOI: 10.1007/s12094-022-02860-5
• Publication Date: 2022-06-06T17:02:51Z
• Authors: Manuel Sánchez Cá...; David Fernández G...; Laura Ortega Moran; Jaime Rubio Pérez; Carlos Miguel Gui...; Miriam Lobo de Mena; Berta Obispo Portero; Jesús Brenes Castro; Yolanda Lage; Diego Cacho Lavin; Ana Belen Rupérez...; Ana Manuela Martí...; Jonatan Zacarías ...; Laura Jiménez Colomo; Noel Blaya Boluda; Javier Bosque Moreno; Teresa Quintanar ...; Carmen Rosa Garrido; Roberto Martín Hu...; Carme Font i Puig; Andrés Jesús Muño...
• Keywords: Oncología Médica; Lung Neoplasms; Tromboembolia Venosa; Pronóstico; Thrombosis; Venous Thromboembolism; Inhibidores de Puntos de Control Inmunológico; Medical Oncology; Prognosis; 3. Good health; Trombosis; 03 medical and health sciences; 0302 clinical medicine; Neoplasias Pulmonares; Cancer related thrombosis; Humans; Lung cancer; Immune Checkpoint Inhibitors; Melanoma; Research Article; Retrospective Studies

Abstract Purpose Immune Checkpoint Inhibitors (ICI) can be associated with thrombotic events, both venous and arterial (VTE/AT). However, there is a paucity of information regarding patients in routine clinical practice. Methods/patients Retrospective, multicenter study promoted by the Thrombosis Cancer Section Spanish Society Medical Oncology (SEOM). Patients melanoma lung cancer who initiated ICI between 01/01/2015 31/12/2019 were recruited. Minimum follow-up was 6 months (unless it not possible because death). The primary objective to calculate incidence ICI-associated VTE/AT secondary objectives included analyze its impact on survival identify predictor variables for VTE/AT. Results 665 enrolled. during 8.4%. Median overall (OS) lower group (12 95% CI 4.84–19.16 vs. 19 16.11–21.9; p = 0.0049). Neutrophil/lymphocyte ratio (NLR) anemia upon initiation IT, as well history thrombosis diagnosis start ICI, predictive developing ( < 0.05). 291 There 5.8% rate follow-up. OS (10 0.0–20.27 29 19.58–36.42; 0.034). NLR lactate dehydrogenase (LDH) at beginning Conclusions increases risk melanoma, which OS.